In studies of HCC patients undergoing local ablation, it has been shown that AFP can act as a tumor associated antigen (TAA), inducing a specific CD8+ T cell response that impacts patient prognosis [47]. The gene discussed is CD8A; the disease is hepatocellular carcinoma.